Search

Your search keyword '"Wedzicha, Jadwiga A"' showing total 97 results

Search Constraints

Start Over You searched for: Author "Wedzicha, Jadwiga A" Remove constraint Author: "Wedzicha, Jadwiga A" Publication Type Conference Materials Remove constraint Publication Type: Conference Materials
97 results on '"Wedzicha, Jadwiga A"'

Search Results

1. Recognising exacerbations in Early COPD

2. Association of a polygenic risk score for chronic obstructive pulmonary disease with lung function across the lifespan

3. Mucus, microbiomes, and lung function decline in COPD

4. Coronary artery disease, COPD exacerbation and inflammation

5. RSV as a Cause of Exacerbations of COPD

7. Fibrinogen as a biomarker of cardiovascular risk in COPD

9. COPD Assessment Test (CAT) Score according to the presence/absence of accelerated lung function decline in young adult smokers with normal FEV1

10. Phenotyping asthma with airflow obstruction in middle-aged and older adults: a CADSET Clinical Research Collaboration

13. Prevalence and characteristics of asthma with fixed airflow obstruction:a CADSET European multi-cohort collaboration

14. Update on CADSET (Chronic Airway Disease Early Stratification) Clinical Research Collaboration

15. COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels

17. Spirometric phenotypes from early childhood to young adulthood – A CADSET (Chronic Airway Disease Early Stratification) study

18. Collating data from major European population studies – The CADSET (Chronic airway disease early stratification) clinical research collaboration

19. Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis

21. A CADSET WP4 transcriptomic analysis of Asthma and COPD overlap

24. Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial

27. Targeted Retreatment of Incompletely Resolved COPD Exacerbations With Ciprofloxacin

39. Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study

50. Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study

Catalog

Books, media, physical & digital resources